Dopamine is a critical neurotransmitter, acting as a chemical messenger in the brain to transmit signals between neurons. Dopamine regulates voluntary movement, drives reinforcement learning, and inhibits prolactin secretion from the anterior pituitary, which is how one molecule works as a neurotransmitter inside the brain and as a hormone in the periphery.
Dopamine's function in addiction is reinforcement: dopamine tags a rewarding event as worth repeating rather than producing the pleasure itself.
The brain synthesizes dopamine from tyrosine, an amino acid supplied by protein-rich food, through a 2-step conversion that runs first to L-dopa and then to dopamine.
Dysregulated dopamine signaling produces 3 distinct conditions: addiction, Parkinson disease, and major depressive disorder, and the direction of the dysregulation differs in each.
What is dopamine?
Dopamine is a catecholamine neurotransmitter and hormone that carries signals across the synaptic cleft between neurons and, outside the brain, acts on receptors in the kidney, gut, and blood vessels. A burst of dopamine follows a rewarding or euphoric experience, which is the link to addiction. That dopamine burst marks the event as worth repeating, and repeated marking of the same cue is what shifts voluntary use toward compulsive use. Wolfram Schultz established what the burst encodes, a reward prediction error, meaning the gap between the reward expected and the reward received: dopamine neurons fire above baseline for an unexpected reward, hold at baseline for a fully predicted one, and dip below baseline when the reward arrives smaller than predicted.
Dopamine belongs to the monoamines, a class of neurotransmitters built from one amino group joined to an aromatic ring by a two-carbon chain. Serotonin, norepinephrine, and epinephrine are the other monoamines the brain uses, and decarboxylase enzymes build each of them from an aromatic amino acid precursor.
What is the role of dopamine in addiction?
Dopamine drives addiction by strengthening the link between a drug cue and the act of using until a chosen behavior becomes a compulsive one. Extracellular dopamine, the concentration of dopamine in the fluid outside the neuron, rises in the nucleus accumbens when a person takes an addictive substance. The nucleus accumbens is the striatal structure that mesolimbic dopamine neurons target, and Wise, Roy A. and Robble, Mykel A. documented that elevation across most addictive drugs in "Dopamine and Addiction," Annual Review of Psychology, volume 71, pages 79 to 106, 2020.
Repeated dopamine release strengthens the synapses that connect a cue to an action, which moves the behavior from deliberate choice toward habit. Dopamine also encodes the cues surrounding a rewarding event. Encoded cues then drive cue-triggered seeking, the behavioral signature clinicians assess as craving. Robinson, Terry E. and Berridge, Kent C. named this mechanism incentive salience in "The neural basis of drug craving: an incentive-sensitization theory of addiction," Brain Research Reviews, volume 18, pages 247 to 291, 1993, defining it as the wanting a cue acquires rather than the pleasure it delivers.
The following 4 features of addiction trace to dopamine signaling.
- Reward signaling: dopamine marks the drug's effect as better than predicted, which makes the act worth repeating.
- Tolerance: reduced D2 availability means the same dose produces a smaller signal, so intake climbs.
- Withdrawal and relapse: reward signaling to food, work, and social contact stays blunted after the drug stops, which is the state relapse relieves.
- Loss of control: Repeated substance use downregulates D2 receptors in the striatum and weakens prefrontal control over reward-seeking, which sustains the addiction cycle.
How does repeated substance use change dopamine pathways?
Repeated substance use lowers the reward system's baseline, so the same dose delivers less reward and the drug's absence delivers more distress. Koob, George F. and Le Moal, Michel named that shift hedonic homeostatic dysregulation in "Drug Abuse: Hedonic Homeostatic Dysregulation," Science, volume 278, pages 52 to 58, 1997.
Continued use downregulates D2 receptor availability, which blunts the signal each release produces rather than reducing how much dopamine the neuron makes. A person with a substance use disorder escalates the dose to reach the same effect, and ordinary rewards such as food and social contact lose their pull as drug seeking takes priority.
What is the function of dopamine?
Dopamine serves 3 functions the brain depends on: it assigns reward value in the mesolimbic pathway, it initiates and scales voluntary movement in the nigrostriatal pathway, and it supports working memory and emotional regulation in the mesocortical pathway. Each pathway is described below.
1. Reward and Pleasure Pathways
The mesolimbic pathway runs from the ventral tegmental area to the nucleus accumbens and carries the brain's reward signal. Rewarding activity releases dopamine along that pathway, which tags the event for storage in memory.
2. Motivation and reinforcement
Dopamine release after a reward stores 2 pieces of information.
- The stimulus that produced the reward, such as food, sex, or a drug.
- The environmental cues present at the time, including the people, the place, the hour, and the activity.
Dopamine produces wanting rather than liking. Opioid and endocannabinoid signaling in the nucleus accumbens carries the hedonic component, and dopamine assigns the motivational pull that returns a person to the cue, which is why craving outlasts enjoyment in a substance use disorder.
3. Regulation of mood and emotions
Dopamine works with oxytocin, endorphins, and serotonin to set mood and emotional tone. Dopamine deficiency in the nigrostriatal pathway produces the motor signs of Parkinson disease, and blunted dopamine signaling contributes to the anhedonia of major depressive disorder. Excess mesolimbic dopamine signaling runs the opposite direction and drives the positive symptoms of psychosis, hallucinations and delusions, which is why the FDA label for haloperidol attributes the drug's effect to antagonism at central dopamine type 2 receptors rather than to raising dopamine.
How is dopamine produced?
Dopamine production runs in 2 enzymatic steps inside dopaminergic neurons, converting the dietary amino acid tyrosine to L-dopa and then L-dopa to dopamine. Poultry, beef, legumes, and low-fat dairy supply the tyrosine. Large neutral amino acid transporters carry tyrosine across the blood-brain barrier, where tyrosine hydroxylase converts it to L-dopa and aromatic L-amino acid decarboxylase converts L-dopa to dopamine. Tyrosine hydroxylase is the rate-limiting enzyme of that pathway, so it sets the ceiling on synthesis. Monoamine oxidase and catechol-O-methyltransferase are the two enzymes that later degrade dopamine.
Newly made dopamine is loaded into synaptic vesicles and held at the presynaptic terminal until an electrical signal arrives. Release lands in the synaptic cleft, the gap between one neuron's terminal and the receptor surface of the next.
How is dopamine released?
Dopamine release follows a 6-step sequence that starts with neuron stimulation and ends with reuptake or enzymatic breakdown. Liu, Changliang and Kaeser, Pascal S. reviewed the release apparatus in "Mechanisms and regulation of dopamine release," Current Opinion in Neurobiology, volume 57, pages 46 to 53, 2019.
- Neuron stimulation: an internal process or an external stimulus excites a dopaminergic neuron, which fires an action potential, the electrical impulse that travels down the axon to the terminal.
- Calcium influx: the action potential reaches the presynaptic terminal and opens voltage-gated calcium channels, and the calcium that enters triggers the release machinery.
- Vesicle fusion: calcium prompts dopamine-filled synaptic vesicles to fuse with the presynaptic membrane and empty into the cleft.
- Dopamine release: dopamine crosses the synaptic cleft to the postsynaptic membrane.
- Receptor binding: dopamine binds D1-like and D2-like receptors on the postsynaptic neuron, and the family it reaches determines whether cyclic AMP inside the receiving cell rises or falls.
- Clearance: the dopamine transporter pumps dopamine back into the presynaptic neuron, and enzymes degrade what remains. Receptor availability then adjusts to the average signal, which is the step repeated drug use distorts.
What happens to dopamine receptors during withdrawal?
Dopamine receptors downregulate during active substance use and upregulate once the substance stops, which is the adaptation behind both tolerance and the discomfort of early abstinence.
Upregulation restores the receptor availability that repeated large dopamine surges had reduced. Sensitivity climbs with it, so natural rewards register again at the intensity they had before.
Receptor downregulation produces the mood disturbance and craving that people report during withdrawal management, because the reward circuit is calibrated to a supply that is no longer arriving.
Dopamine transporter binding recovers across 12 to 17 months of abstinence, per Volkow et al., 2001, The Journal of Neuroscience, and responsiveness to natural rewards such as food and social contact returns, if the person sustains that abstinence.
Does addiction treatment restore dopamine function?
Addiction treatment programs treat substance use disorders and address the receptor changes that repeated use produces, and the receptor recovery that follows scales with the length of abstinence. Repeated intake of addictive drugs downregulates D2 receptor availability, which flattens the response to non-drug rewards such as food, work, and social contact. Dopamine acts through 2 receptor families, D1-like and D2-like, and D2 availability is the measure that falls.
Addiction treatment targets the reinforcement mechanism rather than the dopamine level itself, through the 3 components below.
- Medication-assisted treatment: buprenorphine occupies the mu-opioid receptor as a partial agonist and naltrexone blocks it as an antagonist, which removes the reinforcement an opioid delivers and steadies the reward circuit. Valley Spring Recovery Center provides medication-assisted treatment and does not provide methadone.
- Behavioral therapies: cognitive behavioral therapy retrains the response to a drug cue, and contingency management pays a tangible incentive for each verified negative drug test, which substitutes a reliable non-drug reward for the drug reward.
- Relapse prevention: people in treatment learn to identify the cues that trigger craving and to rehearse a response to each one, which weakens the cue-to-use link the reward circuit built.
The 2004 study by Greenfield, L. et al. in The American Journal of Drug and Alcohol Abuse reports that longer time in treatment predicts higher post-treatment abstinence. Greenfield and colleagues pooled 3 national studies of women in long-term residential care and found abstinence rates of 68 to 71 percent among women who stayed 6 months or longer, which makes retention, rather than any single program feature, the variable that tracked outcome and the reason continuing care matters for preventing relapse.
How do dopamine levels affect serotonin?
Serotonin and dopamine act in opposition, and the documented direction runs from serotonin to dopamine: serotonergic neurons of the dorsal raphe nucleus inhibit midbrain dopamine neurons through 5-HT2C receptors sitting on GABAergic interneurons in the ventral tegmental area. Neurotransmitter balance, rather than the reading on any single messenger, governs mood, appetite, and sleep, so a high value on one system does not predict a low value on the other.
How does marijuana affect dopamine?
Delta-9-tetrahydrocannabinol, the psychoactive constituent of marijuana, binds CB1 receptors on GABAergic interneurons in the ventral tegmental area and disinhibits dopaminergic neurons, which raises striatal dopamine release acutely, while long-term heavy use is associated with blunted striatal dopamine release. Bloomfield, Michael A. P., Ashok, Abhishekh H., Volkow, Nora D. and Howes, Oliver D. reported both findings in "The effects of delta-9-tetrahydrocannabinol on the dopamine system," Nature, volume 539, pages 369 to 377, 2016, where reduced dopamine release among people who used cannabis tracked inversely with the severity of their use.
What is the definition of dopamine addiction?
The definition of dopamine addiction is a lay term rather than a clinical diagnosis, because neither the DSM-5-TR nor the ICD-11 lists it; the recognized diagnoses are substance use disorder and 2 behavioral addictions, and dopamine is only the reinforcing mechanism.
Those 2 behavioral addictions are gambling disorder, which the DSM-5-TR carries as its only non-substance addictive disorder, and gaming disorder, which the World Health Organization added when the ICD-11 took effect in 2022. Roy A. Wise and Mykel A. Robble reported in "Dopamine and Addiction," Annual Review of Psychology volume 71, pages 79 to 106, 2020, that most addictive drugs raise extracellular dopamine. Raised dopamine is a mechanism. NIDA locates that mechanism inside a 3-region addiction cycle covering the basal ganglia, the extended amygdala, and the prefrontal cortex, so no single neurotransmitter reading establishes a diagnosis. A clinician scores published criteria against the substance or the behavior, never against a dopamine measurement. Read Addiction: Definition, Types, Causes, Effects, and Treatment for the full criteria set, and 15 Behavioral Addictions: Definition, Causes, Effects, and Treatment for the non-substance conditions.
What are the symptoms of low dopamine?
Low dopamine signaling produces anhedonia, blunted motivation, slowed movement, muscle rigidity, resting tremor, and disrupted working memory, and which of those appears depends on which dopamine pathway loses signaling.
Each of the following 3 pathways produces a distinct symptom set.
- Mesolimbic: anhedonia, meaning reduced capacity to feel pleasure from what was rewarding before, and the failure to start effortful behavior even when the reward is still wanted.
- Nigrostriatal: bradykinesia, meaning slowness and shrinking amplitude of voluntary movement, plus rigidity and resting tremor. The National Institute of Neurological Disorders and Stroke reports that most people have lost 60 to 80 percent of the dopamine-producing cells in the substantia nigra by the time motor symptoms appear.
- Mesocortical: difficulty holding and manipulating information across seconds, because prefrontal working memory falls off when dopamine sits either below or above a narrow optimal range.
No blood test or consumer neurotransmitter panel measures dopamine signaling in the brain, and neither the DSM-5-TR nor the ICD-11 lists dopamine deficiency as a diagnosis. The FDA approved ioflupane I 123 for striatal dopamine transporter imaging by SPECT in suspected parkinsonian syndromes, and that scan reads transporter density rather than a dopamine level.
How do you increase dopamine naturally?
Dopamine synthesis and receptor availability rise with tyrosine-rich protein, structured aerobic exercise, and 7 or more hours of sleep a night, because each input either supplies the precursor or restores the receptors that read the signal.
The 3 inputs below each carry a measured human finding.
- Protein at meals supplies tyrosine, the precursor covered in the production section above. Tyrosine competes with the other large neutral amino acids for the same transporter, so a meal's amino acid mix, and not protein volume alone, sets how much reaches the brain.
- Supervised aerobic training rebuilds receptor availability. Robertson, Chelsea L. et al. randomized 19 adults in treatment for methamphetamine use disorder to 1 hour of exercise 3 days a week for 8 weeks or to equal-time health education, and only the exercise group gained striatal D2/D3 binding, in Neuropsychopharmacology, volume 41, pages 1629 to 1636, 2016.
- Sleep of 7 or more hours protects what a short night costs. Volkow, Nora D. et al. scanned 20 adults after rested sleep and again after 1 night of sleep deprivation, and D2/D3 availability in the ventral striatum fell, in Journal of Neuroscience, volume 32, pages 6711 to 6717, 2012. The American Academy of Sleep Medicine sets 7 or more hours a night as the adult target.
No dietary supplement is FDA-approved to raise brain dopamine, because the Dietary Supplement Health and Education Act does not authorize pre-market approval of supplements for effectiveness. These 3 inputs support recovery and do not replace treatment for a substance use disorder.
What is a dopamine detox?
A dopamine detox is a stimulus-control exercise that removes high-reward cues for a set period, not a procedure that lowers dopamine, because abstaining from a behavior does not deplete a neurotransmitter the brain synthesizes continuously.
Cameron Sepah, a clinical psychologist, published "The Definitive Guide to Dopamine Fasting 2.0" in October 2019 and built it on stimulus control, the cognitive behavioral therapy technique of removing the cues that trigger a habit. Sepah has since said the name misleads, because the target was the behavior and never the molecule.
The practice interrupts cue-driven behavior. It does not clear, deplete, or reset dopamine, and receptor availability shifts across weeks of changed exposure rather than across a 24-hour fast. Medically supervised withdrawal management is a separate level of care that treats physical dependence under clinical monitoring, and Valley Spring Recovery Center refers people out for it before admitting them to partial care, intensive outpatient, or outpatient treatment.